68Ga标记二聚环肽用于Nectin-4靶向PET显像:从临床前评估到乳腺癌首次人体显像
本研究开发了靶向Nectin-4的68Ga标记二聚环肽PET示踪剂[68Ga]Ga-TDN1,临床前显示高亲和力(K D = 1.92 × 10-10 M)及特异性肿瘤摄取,并在6例乳腺癌患者中开展首次人体PET/CT,与[18F]FDG PET/CT直接比较,示踪剂耐受良好,原发灶及多数淋巴结转移显像性能相当,部分患者骨和肝转移摄取更高、病灶检出改善。
要点
- [68Ga]Ga-TDN1对Nectin-4具有高亲和力,临床前显示特异性肿瘤摄取。
- 首次人体研究纳入6例乳腺癌患者,示踪剂耐受良好,生物分布和剂量学良好。
- 与原发灶及多数淋巴结转移的[18F]FDG PET/CT显像性能相当,部分患者骨和肝转移摄取更高、检出改善。
核心结论
- [68Ga]Ga-TDN1是临床可转化的Nectin-4靶向PET示踪剂,具有高亲和力、良好药代动力学和特异性肿瘤摄取,支持进一步临床评估用于Nectin-4表达无创显像,尤其转移性疾病评估。
研究设计与样本
- 临床前研究构建TDN1并通过点击化学偶联两个Nectin-4结合双环肽,用68Ga标记,通过表面等离子共振评估亲和力,在Nectin-4阳性和阴性肿瘤模型中进行细胞摄取、阻断、小动物PET/CT和生物分布研究,并与[68Ga]Ga-N188比较。
- 临床前评估后开展首次人体试点研究,纳入6例乳腺癌患者行[68Ga]Ga-TDN1 PET/CT,并与[18F]FDG PET/CT直接比较。
主要发现
- TDN1对Nectin-4显示高亲和力(K D = 1.92 × 10-10 M)。
- 临床前研究中[68Ga]Ga-TDN1在Nectin-4阳性细胞和肿瘤中显示特异性摄取,在Nectin-4阴性模型中摄取低,阻断条件下摄取明显降低。
- 与[68Ga]Ga-N188相比,[68Ga]Ga-TDN1在多个Nectin-4阳性异种移植瘤中显示更高的肿瘤摄取和更长的滞留。
- 首次人体研究中[68Ga]Ga-TDN1耐受良好,显示良好的生物分布和剂量学。
- [68Ga]Ga-TDN1 PET/CT对原发灶和多数淋巴结转移的显像性能与[18F]FDG PET/CT相当,在部分患者中骨和肝转移显示更高摄取和改善的病灶检出。
临床怎么用
- [68Ga]Ga-TDN1 PET/CT可用于无创评估乳腺癌患者的Nectin-4表达,尤其用于转移性疾病评估,部分骨和肝转移灶检出优于[18F]FDG PET/CT。
局限性
- 首次人体研究为试点研究,仅纳入6例乳腺癌患者,样本量小,需进一步临床评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nectin-4 is an attractive target for molecular imaging and targeted therapy because of its overexpression in multiple malignancies. We developed a nectin cell adhesion molecule 4 (nectin-4)-targeted 68Ga-labeled dimeric cyclic peptide PET tracer, [68Ga]Ga-TDN1, for noninvasive imaging of nectin-4 expression. Methods: TDN1 was generated by click chemistry to conjugate 2 nectin-4-binding bicyclic peptides and was radiolabeled with 68Ga. Binding affinity was assessed by surface plasmon resonance. Target specificity and tumor-targeting ability were evaluated by cell uptake, blocking, small-animal PET/CT, and biodistribution studies in nectin-4-positive and nectin-4-negative tumor models. [68Ga]Ga-TDN1 was further compared with [68Ga]Ga-N188 in preclinical models. After preclinical evaluation, [68Ga]Ga-TDN1 PET/CT was investigated in a pilot first-in-human study in 6 patients with breast cancer and directly compared with [18F]FDG PET/CT. Results: TDN1 showed high affinity for nectin-4 (K D = 1.92 × 10-10 M). In preclinical studies, [68Ga]Ga-TDN1 showed specific uptake in nectin-4-positive cells and tumors, low uptake in nectin-4-negative models, and marked reduction in uptake under blocking conditions. Compared with [68Ga]Ga-N188, [68Ga]Ga-TDN1 showed higher tumor uptake and longer retention across multiple nectin-4-positive xenografts. In the pilot clinical study, [68Ga]Ga-TDN1 was well-tolerated and showed favorable biodistribution and dosimetry. [68Ga]Ga-TDN1 PET/CT revealed imaging performance comparable to that of [18F]FDG PET/CT for primary tumors and most nodal metastases and demonstrated higher uptake and improved lesion detection in bone and liver metastases in selected patients. [68Ga]Ga-TDN1 was a clinically translatable nectin-4-targeted PET tracer with high affinity, favorable pharmacokinetics, and specific tumor uptake. Preclinical and pilot clinical results supported further clinical evaluation of [68Ga]Ga-TDN1 for noninvasive imaging of nectin-4 expression, particularly for assessment of metastatic disease.
引用
- Ge S, Li J, Shi J, et al. 68Ga-Labeled Dimeric Cyclic Peptide for Nectin-4-Targeted PET Imaging: From Preclinical Evaluation to First-in-Human Imaging in Breast Cancer. J Nucl Med. 2026. PMID: 42850038. doi:10.2967/jnumed.126.273306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。